Clinical Trials on Glycogen Hepatopathy in United States
Total 130 results
-
Duke UniversityKriya TherapeuticsRecruitingGlycogen Storage Disease VI | GLYCOGEN STORAGE DISEASE IXa1 | GLYCOGEN STORAGE DISEASE IXa2 | Glycogen Storage Disease IXB | Glycogen Storage Disease IXC | GSD 9 (All Subtypes) | GSD 6United States
-
United States Army Research Institute of Environmental...Completed
-
ReGenTree, LLCTerminatedNeurotrophic KeratopathyUnited States
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
Sanguine BiosciencesTerminatedGlycogen Storage Disease Type IBUnited States
-
Oyster Point Pharma, Inc.CompletedNeurotrophic KeratopathyUnited States
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
ReGenTree, LLCRecruitingNeurotrophic KeratopathyUnited States
-
Areeg El-GharbawyUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IUnited States
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
University of FloridaPrometheus LaboratoriesCompletedInflammatory Bowel Disease | Glycogen Storage Disease Type IaUnited States
-
Javier Gonzalez, PhDMaastricht University; University of Newcastle Upon-Tyne; Sugar Nutrition, UKCompletedLiver and Muscle Glycogen Use During Exercise.United Kingdom
-
Duke UniversityCompleted
-
Northumbria UniversityNewcastle University; Maastricht University; Sugar NutritionCompletedLiver and Muscle Glycogen Replenishment Post-exerciseUnited Kingdom
-
Duke UniversityGenzyme, a Sanofi CompanyCompletedNeuropathy | Myopathy | Glycogen Storage Disease Type II (Late-onset Pompe Disease)United States
-
Duke UniversityRecruitingAdult Polyglucosan Body Disease | Glycogen Storage Disease Type IV | GSD4 | GSD IV | APBDUnited States
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IIIUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease Late-Onset | Glycogen Storage Disease Type II GSD IIUnited States
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Netherlands
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Spain, Italy
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II)United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
-
Amicus TherapeuticsRecruitingGlycogen Storage Disease Type II Infantile OnsetUnited States, Taiwan, France, Germany, Italy, United Kingdom
-
Columbia UniversityWithdrawnGlycogen Storage Disease Type IIUnited States
-
ModernaTX, Inc.RecruitingGlycogen Storage DiseaseUnited States, Canada
-
Rigshospitalet, DenmarkUniversity College, LondonCompletedMcArdle DiseaseDenmark, United Kingdom
-
Reneo Pharma LtdCompletedMcArdle DiseaseSpain, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyActive, not recruitingGlycogen Storage Disease Type II-Pompe's DiseaseUnited States, France, Japan, Taiwan, United Kingdom
-
Duke UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedGlycogen Storage Disease Type IIUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase DeficiencyUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPompe DiseaseUnited States
-
University of FloridaCompletedPompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyTerminatedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Israel
-
National Institute of Arthritis and Musculoskeletal...CompletedMyositis | Dermatomyositis | Polymyositis | Glycogen Storage Disease Type II | Glycogen Storage Disease Type VIIUnited States
-
Duke UniversitySanofiRecruiting
-
Duke UniversityGenzyme, a Sanofi CompanyRecruitingPompe DiseaseUnited States
-
University of California, IrvineGenzyme, a Sanofi CompanyCompletedPompe DiseaseUnited States
-
Amicus TherapeuticsTerminated
-
University of FloridaTerminated
-
O & O Alpan LLCCompleted
-
University College, LondonCompleted
-
Valerion Therapeutics, LLCTerminatedPompe DiseaseUnited States, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II Pompe DiseaseUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Spark TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Italy, United Kingdom, Netherlands, France, Germany
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of FloridaLacerta TherapeuticsCompletedPompe DiseaseUnited States
-
University of FloridaBioMarin PharmaceuticalCompleted
-
University of FloridaAmicus TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type II | Pompe DiseaseUnited States